-

Alexion to Discuss Key Pipeline Programs at Virtual Investor Day

BOSTON--(BUSINESS WIRE)--Alexion Pharmaceuticals (Nasdaq:ALXN) a biotechnology company focused in rare disease development and commercialization, today announced that the company will host a Virtual Investor Day on Tuesday, October 6th, 2020 from 8:00 a.m. to 12:00 p.m. ET. Management will highlight continued strategic advancement, including key pipeline opportunities and drivers of future growth.

An audio webcast of the presentation will be available live. More details will be available at http://ir.alexion.com leading up to the event. An archived version of the remarks will also be available through the Company’s website for a limited time following the conference.

[ALXN-G]

Contacts

Investors
Chris Stevo
Head of Investor Relations
(857) 338-9309

Media
Megan Goulart
Executive Director, Corporate Communications
(857) 338-8634

Industry:

Alexion Pharmaceuticals

NASDAQ:ALXN
Release Summary
Alexion to Discuss Key Pipeline Programs at Virtual Investor Day
Release Versions
English

Contacts

Investors
Chris Stevo
Head of Investor Relations
(857) 338-9309

Media
Megan Goulart
Executive Director, Corporate Communications
(857) 338-8634

More News From Alexion Pharmaceuticals

Alexion Announces Positive Topline Results from Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Adults with Generalized Myasthenia Gravis (gMG)

BOSTON--(BUSINESS WIRE)--Alexion Announces Positive Topline Results from Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Adults with Generalized Myasthenia Gravis (gMG)....

Caelum and Alexion Present Additional Phase 2 Data Reinforcing Safety and Tolerability of CAEL-101 in AL Amyloidosis at the European Hematology Association Congress 2021

BORDENTOWN, N.J. & BOSTON--(BUSINESS WIRE)--Caelum and Alexion Present Additional Phase 2 Data Reinforcing Safety and Tolerability of CAEL-101 in AL Amyloidosis at the EHA Congress 2021...

 Alexion Announces FDA Approval of ULTOMIRIS® (ravulizumab-cwvz) for Children and Adolescents with Paroxysmal Nocturnal Hemoglobinuria (PNH)

BOSTON--(BUSINESS WIRE)--Alexion Announces FDA Approval of ULTOMIRIS® (ravulizumab-cwvz) for Children and Adolescents with Paroxysmal Nocturnal Hemoglobinuria (PNH)...
Back to Newsroom